Page last updated: 2024-12-07

5-ethynyl-1-ribofuranosylimidazole-4-carboxamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5-ethynyl-1-ribofuranosylimidazole-4-carboxamide: used in therapy of experimental leukemia [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122653
SCHEMBL ID18719588
MeSH IDM0164462

Synonyms (6)

Synonym
118908-07-9
1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynylimidazole-4-carboxamide
1h-imidazole-4-carboxamide, 5-ethynyl-1-beta-d-ribofuranosyl-
5-ethynyl-1-ribofuranosylimidazole-4-carboxamide
5-erfic
SCHEMBL18719588

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Other IMP dehydrogenase inhibitors administered near maximum tolerated doses using the same dosing regimen as for ribavirin were found to slightly enhance virus replication in the lungs."( Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.
Bailey, K; Barnard, DL; Carson, DA; Cottam, HB; Day, CW; Heiner, M; Hoopes, J; Lauridsen, L; Lee, J; Li, JK; Montgomery, R; Sidwell, RW; Winslow, S, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (4.76)18.7374
1990's10 (47.62)18.2507
2000's7 (33.33)29.6817
2010's3 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index5.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.76%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]